A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers
A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Zuidlaren, Netherlands, 9471 GP
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult male and female volunteers, 18 - 64 years of age, inclusive Healthy status is defined by absence of evidence of any active or chronic disease following detailed medical and surgical history and a complete physical examination
- Body mass index (BMI) 18 to 30 kg/m2 inclusive
- Female subject must be post-menopausal or surgically sterile
- Male subjects with female partners of child-bearing potential must use two methods of contraception, one of which must be a barrier method, for the duration of the study and for at least 30 days after the last dose of study drug
Exclusion Criteria:
- History of any clinically significant disease or disorder
- Concomitant disease or condition that could interfere with, or the treatment of which might interfere with, the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
- Clinically significant abnormalities in laboratory test results
- Suspicion of regular consumption of drug of abuse
- Positive for hepatitis B, hepatitis C or HIV infection
- Participation in an investigational drug or device study within 90 days prior to screening
- Regular smoker (>5 cigarettes, >1 pipeful or >1 cigar per day)
- History of clinically significant hypersensitivity or allergic drug reactions
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
|
Multiple ascending doses
|
|
Experimental: RO5545965
|
Multiple ascending doses
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Safety: Incidence of adverse events
Time Frame: approximately 3 months
|
approximately 3 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Pharmacokinetics: Area under the concentration-time curve (AUC)
Time Frame: 17 days
|
17 days
|
|
Pharmacokinetics: Plasma concentrations
Time Frame: 17 days
|
17 days
|
|
Pharmacokinetics: Urine concentrations
Time Frame: 13 days
|
13 days
|
|
Pharmacodynamics: Serum prolactin levels
Time Frame: Day 12
|
Day 12
|
|
Pharmacodynamics: Glucose tolerance test
Time Frame: Day 11
|
Day 11
|
|
Pharmacodynamics: Probabilistic learning tasks
Time Frame: Days 6, 8 and 10
|
Days 6, 8 and 10
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- BP28845
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.